previous compound ID: 713 next compound
InChIKey: GIIZNNXWQWCKIB-UHFFFAOYSA-N
SMILES: C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O

biological descriptors:

CFTR relevance: unspecified

Category:
Influence on CFTR function unknown
Order of interaction unknown
subcellular compartment unknown

reference list:

ReferenceID: 53
"E Matthes" "J Goepp" "GW Carlile" "B Kus" "J Liao" "DY Thomas" "R Robert" "D Rotin" "JW Hanrahan" "SD Macknight"

chemical graph of compound 713





CID is 5152
synonyms found at PubChem are:
Salmeterol, 89365-50-4, Serevent, Aeromax, Astmerole, Salmeterolum [Latin], Salmeterolum, GR 33343X, SALMATEROL, Salmeterol [USAN:BAN:INN], HSDB 7315, Salmeterol (USAN/INN), 136112-01-1, 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol, 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol, CHEBI:64064, GIIZNNXWQWCKIB-UHFFFAOYSA-N, GR-33343X, (+-)-4-Hydroxy-alpha'-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol, (+-)-4-Hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol, Salmeterol Fluticasone Propionate Mixture, CPD000466295, S 2692, Q-101428, 1,3-Benzenedimethanol, 4-hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-, 2-(hydroxymethyl)-4-[1-hydroxy-2-({6-[(4-phenylbutyl)oxy]hexyl}amino)ethyl]phenol, 4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)-2-(hydroxymethyl)phenol, 1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-, 1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl-, (+-)-, SMR000466295, SR-01000076139, Salmeterol [USAN:INN:BAN], SN408D, 4-(1-hydroxy-2-((6-(4-phenylbutoxy)hexyl)amino)ethyl)-2-(hydroxymethyl)phenol, NCGC00025247-01, Fluticasonepropiponate, AC1L1JPX, Glaxo Wellcome brand of salmeterol xinafoate, Prestwick3_000945, ACMC-1C1VM, DSSTox_CID_3571, D0L5YV, SCHEMBL4767, CHEMBL1263, DSSTox_RID_77087, DSSTox_GSID_23571, Lopac0_001100, BSPBio_000910, GTPL559, MLS000759000, MLS001424322, BPBio1_001002, DTXSID6023571, BDBM25771, CTK4C0163, MolPort-005-933-084, HMS2052H13, HMS2090E17, HMS2097N12, HMS3268K19, HMS3394H13, HMS3714N12, BCP04199, KS-00000L6B, SalMeterol Xinafoate Adduct IMpurity, Tox21_113584, CS0057, STK629186, AKOS005561914, AN-6615, API0004131, CCG-101194, CCG-205176, CS-2815, DB00938, GR 33343 X, GR-33343-X, NC00444, 1,3-Benzenedimethanol, 4-hydroxy-.alpha.1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, MRF-0000468, NCGC00015938-03, NCGC00025247-02, ACM136112011, BC202639, CC-34358, HY-14302, K590, LS-29869, SAM001247096, SC-23297, SC-67460, CAS-89365-50-4, KB-146003, AB00513972, FT-0600807, FT-0674509, TL80090037, C07241, D05792, AB00513972-07, 365S504, C-21992, L000532, Salmeterol Impurity H (Xinafoate Adduct Impurity), SR-01000076139-2, SR-01000076139-6, BRD-A01320529-001-05-9, 2-hydroxymethyl-4-{1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl}phenol, 1,3-Benzenedimethanol,4-hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, 5-[2-[6-(4-Phenylbutoxy)hexylamino]-1-hydroxyethyl]-2-hydroxybenzenemethanol, ( inverted question mark) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol; GR 33343X, (inverted question mark) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol, 1-hydroxy-2-naphthoic acid;4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]-2-methylol-phenol